Closing the Wound: A New Patent Aims to Revolutionize Colorectal Surgery

SINGAPORE – July 01, 2026 – In the intricate world of medical technology, progress is often measured in millimeters and single percentage points. But a newly granted U.S. patent to a small Singaporean firm, NICE Surgical Solutions, hints at a more profound leap. The company has secured intellectual property for a novel “purse-string stapler,” a device that promises to fundamentally re-engineer one of the most common and high-risk aspects of colorectal surgery. By enabling surgeons to perform an entire procedure inside the body, it aims to eliminate the need for a large abdominal incision, a practice that has long been a primary source of patient complications.

This development, validated by U.S. Patent No. 12,653,527 B2, is more than just a technical milestone. It represents a potential shift in the structural integrity of surgical care, directly addressing a persistent vulnerability in our healthcare system: the high rate of post-operative infections and complications. Backed by the medtech and agrifood investment firm The Trendlines Group, NICE Surgical is now poised to challenge the status quo, moving towards human clinical trials by the end of 2026.

A New Blueprint for Internal Repair

At the heart of the innovation is a procedure known as intracorporeal anastomosis—the surgical reconnection of the bowel entirely within the abdominal cavity. For decades, even in minimally invasive laparoscopic surgeries, surgeons often had to make a small but significant incision to pull a portion of the bowel outside the body to perform the reconnection (extracorporeal anastomosis). While less invasive than traditional open surgery, this step still exposes internal tissues, requires manual handling of the bowel, and creates a wound that is a prime candidate for infection.

The NICE Surgical device is designed to make this external step obsolete. It accomplishes three critical tasks—resection (cutting), stapling, and applying a purse-string suture—in a single, efficient firing, all inside the body. This integration is the key. The purse-string suture cinches the open end of the colon closed, preparing it perfectly for a clean, secure, and fully internal connection. The potential benefits, as suggested by a growing body of medical research on intracorporeal techniques, are significant. They include a lower risk of bleeding, less trauma to the intestinal tissue, and a potential reduction in post-operative ileus, a painful and debilitating condition where the bowel temporarily ceases to function.

“Medical innovation transforms scientific discovery into better patient outcomes,” commented the device’s co-founder and inventor, Dr. Eric Haas, Chief of Colorectal Surgery at Houston Methodist Hospital. His involvement lends immense credibility to the project. As a world-renowned expert in minimally invasive colorectal techniques, Dr. Haas’s invention is born from a direct, firsthand understanding of the operating room's limitations and a vision for improving the standard of care.

From the Lab to the Patient's Bedside

The true measure of any medical device is its impact on the patient. Here, the purse-string stapler’s potential is most compelling. Colorectal procedures, while often life-saving, carry the highest rates of surgical site infections (SSIs) among all common surgeries. Recent data showed SSI rates for these procedures climbing to 7.4%, a troubling 21% increase since late 2019. These infections are not minor setbacks; they can lead to prolonged hospital stays, secondary surgeries, increased mortality, and staggering healthcare costs.

By potentially eliminating the need for an abdominal extraction incision, NICE Surgical’s device strikes at the root cause of many of these SSIs. “Any time you can avoid a larger incision, you are fundamentally reducing the patient's risk profile,” noted one independent surgical oncologist not affiliated with the company. “Anastomotic leaks and infections are the two specters that haunt every colorectal surgeon. A technology that can demonstrably lower the incidence of either would be a game-changer.”

Beyond infection control, the patient benefits extend to a more rapid and less painful recovery. Smaller incisions mean less tissue trauma, reduced need for opioid painkillers, and a quicker return to normal life. The risk of developing a future incisional hernia—a common long-term complication of abdominal surgery—is also dramatically reduced. For patients facing a cancer diagnosis or a chronic condition like inflammatory bowel disease, a smoother, faster, and safer surgical experience can have a profound impact on their overall quality of life.

The Strategic Stitch: IP, Investment, and the Medtech Battlefield

For NICE Surgical and its parent investor, The Trendlines Group, this patent is less a finish line and more a fortified starting block. In the fiercely competitive medical device market, dominated by giants like Medtronic and Ethicon, intellectual property is the essential currency for survival and growth. This patent validates the technology and provides a protective moat as the company navigates the expensive and lengthy process of clinical trials and regulatory approval.

Haim Brosh, CEO of Trendlines, framed the patent as a “testament to the dedication and ingenuity” of the research team, noting that it “further strengthens our validated technology.” This is the language of a strategic investor building value. Trendlines operates by incubating early-stage companies, providing not just capital but deep operational expertise to transform an invention into a commercially viable business. The successful patent grant significantly de-risks their investment and makes NICE Surgical a more attractive candidate for future funding rounds or a potential partnership with a major industry player.

The road ahead is still long. The planned human clinical studies, set to begin by Q4 2026, will be the ultimate test. The device must prove not only that it is safe, but that it delivers outcomes superior to the highly advanced powered staplers already on the market. But with a globally recognized surgical innovator at the helm and a strategic investor clearing the path, NICE Surgical is making a credible bid to stitch a new, stronger fabric into the structure of modern surgery.